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Background: Smoking is an undertreated risk factor for coronary artery disease (CAD) and is associated with
adverse outcomes after myocardial infarction. Aims of our study were to determine if management of CAD by
medical therapy (MT) alone or with coronary artery bypass grafting (CABG) or percutaneous coronary intervention
(PCI) influence smoking status at one year following angiography and if a change in smoking status at one year
influences long term survival.
Methods: Prospective cohort study using the APPROACH registry. Two cohorts were examined: (1) 11,334
patients who returned a one year follow-up questionnaire; (2) 4,246 patients propensity-matched based on their
post-angiography treatment - MT or revascularization (RV). Multivariate modeling and survival analysis were used.
Results: In the propensity-matched cohort, quit rates at one year were greater among CABG patients (68%) than
PCI (37%) or MT patients (47%). Smokers in the RV group, who self-reported quitting at one year, had a significantly
reduced mortality compared to those who continued to smoke.
Conclusions: CABG patients were more likely to quit smoking than those treated with MT alone or PCI. Quitting
smoking was associated with improved long-term survival; smoking remains a key risk factor for mortality in patients
with CAD. These data underscore the importance of nicotine addiction management in patients with CAD and the
need to emphasize cessation particularly in those patients undergoing MT or PCI.
Keywords: Smoking cessation, Coronary artery disease, Coronary artery bypass grafting, Percutaneous coronary
interventionBackground
Cigarette smoking is associated with the development of
coronary artery disease (CAD) [1] and influences short
and long term outcomes of patients who smoke after
diagnosis [2-4]. Smoking cessation substantially reduces
the risk of total coronary heart disease mortality [5,6], and
can reduce the need for revascularization procedures [7].
The single most common CAD risk factor among patients
hospitalized for initial myocardial infarction is hypertension* Correspondence: bfinegan@ualberta.ca
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unless otherwise stated.(44%), followed by smoking (23%) [8]. Globally, smoking is
still considered to be responsible for up to one third of the
mortality associated with cardiovascular disease [9]. Des-
pite the availability of smoking cessation therapies and the
publication of excellent guidelines outlining the measures
required to enhance the quit rates of smokers with CAD
[10], there continues to be poor uptake by clinicians and
patients of the behavioural and pharmacological measures
available to assist patients with established CAD to quit
smoking [11].
The objectives of the current study were to assess 1) if
different management strategies: medical therapy alone
(MT), MT and coronary artery bypass grafting (CABG)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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influence quit rates at one year following diagnostic
angiography, and 2) if quitting smoking at one year influ-




The Alberta Provincial Project for Outcomes Assessment
in Coronary Heart disease (APPROACH) registry captures
data on all patients who undergo coronary angiography in
Alberta, Canada. This study reports on data collected be-
tween January 2003 and March 2010. Database and data
collection methods have been previously described in detail
[12]. In brief, data collected includes socio-demographic
characteristics, smoking status, clinical co-morbidities, prior
cardiac events, indication for angiography (which includes
detail regarding a clinical event if present), ejection fraction,
coronary anatomy and all treatments received (MT, CABG,
PCI) following angiography. Clinical indications for angiog-
raphy included acute/recent MI, stable angina, unstable
angina, and other. Data in APPROACH are linked quar-
terly with the Service Alberta Ministry–Vital Statistics to
capture mortality and date of death (99.9% follow up).
All patients in APPROACH who consented to follow-
up during the study period were sent a questionnaire
one year after their index angiography. Two questions
related to tobacco: Do you currently smoke cigarettes?
and If you quit, how long ago did you quit?
The APPROACH study and sub-studies are approved
by the ethical review boards at the University of Alberta
and the University of Calgary.
Statistical analysis
Pearson Chi-Squared test for categorical variables and
t-test for continuous variables were used to compare
baseline clinical characteristics across strata. Patients were
initially stratified based on their smoking status at time of
angiography into current smokers and non-smokers. Pa-
tients were subsequently stratified into four categories
based on their smoking status at angiography and one
year: 1) patients who reported being smokers at baseline
and at follow-up, 2) patients who reported being smokers
at baseline and non-smokers at follow-up, 3) patients who
reported being non-smokers at baseline and at follow-up,
and 4) patients who reported being non-smokers at base-
line and smokers at follow-up. The latter constitute a
small number of patients (n = 64), and were excluded from
further analysis. A Pearson Chi-Squared test was used to
assess the association between the treatment that the pa-
tient received after angiography and smoking status at one
year follow-up.
Two cohorts were examined: Cohort A, the entire group
who returned an analysable questionnaire at one year,and, Cohort B, a group from Cohort A, matched based on
the propensity to undergo revascularization. The propen-
sity score was calculated as the probability of undergoing
revascularization (PCI or CABG) on the observed baseline
(measured at recruitment) characteristics. This technique
allows for a high number of confounding variables and
has been used to create a stratum of subjects who can be
matched on the propensity score whereby exposure is
not confounded with measured baseline covariates. The
propensity score was calculated using logistic regression.
The following variables were included in the model: age,
sex, smoking status, pulmonary disease, cerebrovascular
disease, renal disease, heart failure, diabetes, dialysis, hyper-
tension, hyperlipidemia, liver/GI disease, malignancy, per-
ipheral vascular disease, prior MI, prior PCI, prior CABG,
prior lytic therapy, the indication for angiography includ-
ing MI, stable angina, unstable angina or other, the coron-
ary anatomy and the ejection fraction. Greedy matching
techniques were applied to match patients who were
revascularized to patients who were treated with medical
management by matching the participants with the near-
est propensity score, i.e. within 3 decimal places of
the propensity score for each case. Overlap of propensity
scores between revascularized and medically managed pa-
tients were evaluated using histograms, Chi-Squared values
and probability values. Differences in baseline factors be-
tween groups were calculated before and after propensity
adjustment to assess balance.
Survival analysis was conducted; survival tables and
log rank tests were used to determine if there was a sta-
tistically significant survival difference between revascu-
larized and medically managed patients.
Sensitivity analysis was conducted in order to account
for the effect of disease progress and medical manage-
ment changes over time by splitting the follow up period
into two 45 month periods.
All analyses were conducted using SPSS version 19.0
(IBM SPSS, Armonk, NY).
Results
In all 29,230 patients were invited to complete the
APPROACH survey at one year after their procedure.
The response rate to the survey was 57.4% with 38.7%
returning a fully completed questionnaire that was suit-
able for analysis. Surveys were not sent to the families of
subjects who had died within one year (n = 1968; 6.7% of
total patient population), 33% of those who died were
smokers at time of angiography. Data on the latter group
consisted of demographic and other information collected
at the time of angiography and mortality data obtained
from Service Alberta Ministry – Vital Statistics.
The smoking status of at baseline and at one year for
both Cohorts is shown in (Figures 1 and 2). In Cohort





Cohort A (Unmatched) Cohort B (Matched)
MT MT-PCI MT-CABG
Figure 1 Smoking status at the time of angiography. MT: Medial Treatment, PCI: Percutaneous Coronary Intervention, CABG: Coronary Artery
Bypass Grafting.
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respect to smoking status at time of angiography and as
in Cohort A, CABG patients were more likely to quit.
In Cohort A, patients who smoked were significantly
younger at time of index angiography, were more likely to
present with acute coronary syndrome, to had a prior MI
and to have required an emergency or urgent in-hospital
angiography (Table 1). These differences remained signifi-
cant when patients were stratified according to post-
angiography treatment strategy (Table 2). Additionally,
characteristics of smokers who quit compared with those
who did not quit in Cohort A are shown in Table 3.
The baseline characteristics of Cohort B were remark-
ably well matched (Table 4). There were no significant
differences between initial treatment strategies and sub-
sequent cross-over to another treatment strategy - 86%
and 87% of patients in MT and RV groups did not
undergo any other treatment over the follow-up period
(Table 5). Self-reported smoking cessation rates at one
year following angiography were significantly higher
among CABG patients (68%) than PCI (37%, p < 0.001)
or MT patients (47%, p <0.001) (Figure 2, Table 6).52.4%§
42.6%†*
25.7%
Cohort  A (Unmatched)
MT MT-PC
Figure 2 Smoker who kept smoking at one year after angiography. M
CABG: Coronary Artery Bypass Grafting. †p value PCI vs. MT <0.001; *p
PCI vs. MT = 0.007.Survival analysis
Patients were followed for a mean of 42.2 months (SD
24.9 months). Non-smokers had a significantly higher
long term survival rate compared with smokers in the
RV group (93% vs. 89%, p <0.05), but not in those in
MT (89% vs. 88%, p = 0.8) (Table 7). Smokers at baseline
who had quit at one year had greater long term survival
rate compared with those who continued to smoke after
revascularization (95% vs. 89%, p < 0.05), a trend towards
reduced mortality was also observed in patients in the
MT group (93% vs. 88%, p = 0.2) (Table 7).
Our sensitivity analysis showed no alteration in the
smoking-related survival pattern, however, survival im-
proved for all patients regardless of the index treatment
strategy in the second follow-up period (MT: 85.7% vs.
93.1%; CABG: 84.5% vs. 91.2%; and PCI: 91.4 vs. 96.2%,
first vs. second period, respectively).
Discussion
The overwhelming impact of tobacco smoking on the
time course of the appearance of CAD is illustrated in our





T: Medial Treatment, PCI: Percutaneous Coronary Intervention,
value PCI vs. CABG <0.001; §p value MT vs. CABG <0.001; ‡p value
Table 1 Baseline characteristics stratified by smoking
status at angiography (Cohort A, unmatched)
Clinical characteristics Non-smoker Smoker p-value
No. (%) 8750 (77.2) 2584 (22.8)
Age, Mean (SD) 66.4 (10.4) 58.7 (9.8) <0.001
Female (%) 21.8 22.4
Diabetes Mellitus (%) 22.9 19.6 <0.001
Hyperlipidemia (%) 78.5 79.2
Pulmonary disease (%) 12.6 14.0
Heart Failure (%) 8.7 9.1
Hypertension (%) 70.5 62.6 <0.001
CVD (%) 5.9 4.1 <0.001
PVD (%) 5.9 7.2 0.015
ST-Elevated MI (%) 21.5 38.2 <0.001
Non ST-Elevated MI (%) 21.9 29.3 <0.001
Prior MI (%) 22.4 24.9 0.008
Prior PCI (%) 4.8 3.3 0.001
Prior CABG (%) 3.7 1.4 <0.001
Prior lytic (%) 4.8 10.6 <0.001
ACS (%) 55.5 73.8 <0.001
Indication for angiography (%) <0.001
Stable angina 37.7 20.7
MI 38.9 60.0
Unstable angina 18.6 15.1
Other* 4.9 4.1
Priority to angiography (%) <0.001
Emergency 10.5 16.1
Urgent in Hospital 47.2 59.0
Urgent out of hospital 14.5 9.2
Planned 27.1 14.4
Unknown 0.8 1.3





Not done 8.7 7.8
Coronary Anatomy (%) <0.001
Normal 0 0
<50% disease 0.2 0.1
Low risk (1–2 VD) 53.2 61.3
High Risk (2–3 VD) 36.7 30.9
Left Main disease 9.8 7.6
Table 1 Baseline characteristics stratified by smoking
status at angiography (Cohort A, unmatched) (Continued)




SD: Standard deviation, BMI: body mass index, CVD: Cerebrovascular disease,
PVD: Peripheral vascular disease, MI: myocardial infarction, PCI: Percutaneous
Coronary Intervention, CABG: Coronary Artery Bypass Grafting, ACS: Acute
coronary syndrome, VD: vessel disease. *Other include silence ischemia,
evaluation of serious arrhythmia, preoperative assessment, research
protocol angiography.
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smokers were more likely to present on an urgent basis
and suffer an STEMI relative to non-smokers. Despite
successful efforts to promote a standardized approach to
the management of patients following acute myocardial
infarction (AMI), the prevalence of smoking in this popu-
lation group has remained largely unchanged over the last
decade [14].
A key treatment goal following the diagnosis of CAD is
to initiate effective secondary prevention measures, in-
cluding nicotine addiction management for those patients
who smoke [10]. Our data point to the importance of re-
habilitation care for smokers following diagnostic or any
procedural interventions, particularly those who undergo
PCI. In Alberta, patients who have been diagnosed with
CAD through angiography are referred to outpatient car-
diac risk management programs. Unfortunately, data on
referral rates by clinicians and uptake of these programs
by patients were unavailable, nevertheless, evidence from
other sources indicate that referral to out-patient cardiac
rehabilitation services remains low [15] especially in the
socially disadvantaged [16]. Recent Medicare data indicate
that those who have undergone CABG are more than
twice as likely as others to use out-patient cardiac rehabili-
tation services [16]. Parashar et al. [17] tracked participa-
tion rates of patients after an AMI enrolled into cardiac
rehabilitation programs after discharge from hospital and
found that current smokers, those with lower socioeco-
nomic status and those who had undergone PCI were the
least likely to participate in the programs.
To our knowledge, this is the largest study to assess
the impact of smoking and smoking cessation on out-
comes in a broad and generalizable propensity matched
cohort. We found a strong association with a lower
survival in patients who smoked who had undergone
revascularization, even after adjusting for key variables
and performing a propensity matching to account for
variations in patient and clinician decisions on further
care.
For smokers with CAD, quitting smoking is the most ef-
fective secondary preventive measure in reducing mortality
Table 2 Baseline characteristics stratified by treatment
(Cohort A)
Clinical characteristics Medical Revascularization p-value
No. (%) 2326 (20.5) 9008 (79.5)
BMI, Mean (SD) 28.8 (5.6) 28.8 (5.1)
Age, Mean (SD) 65.5 (10.8) 64.2 (10.7) <0.001
Female (%) 24.9 21.1 <0.001
Current smoker (%) 19.6 23.6 <0.001
Diabetes Mellitus (%) 26.9 20.9 <0.001
Hyperlipidemia (%) 78.9 78.6
Pulmonary disease (%) 16.3 12.1 <0.001
Heart Failure (%) 13.7 7.5 <0.001
Hypertension (%) 72.8 67.6 <0.001
CVD (%) 7.5 5.0 <0.001
PVD (%) 8.5 5.6 <0.001
ST-Elevated MI (%) 11.7 28.9 <0.001
Non ST-Elevated MI (%) 19.1 24.8 <0.001
Prior MI (%) 28.3 21.6 <0.001
Prior PCI (%) 5.7 4.1 0.001
Prior CABG (%) 7.2 2.1 <0.001
Prior lytic (%) 2.6 7.0 <0.001
ACS (%) 42.8 64.1 <0.001
Indication for angiography (%) <0.001
Acute/recent MI 26.7 48.1
Unstable angina 17.4 17.9
Stable angina 48.1 30.1
Other* 7.8 3.9
Priority to angiography (%) <0.001
Emergency 2.2 14.2
Urgent in hospital 45.5 51.0
Urgent out of hospital 16.8 12.3
Planned 35.4 21.4
Unknown 0.2 1.0





Not done 13.9 15.9
Coronary Anatomy (%) <0.001
Normal 0.2 0.0
<50% disease 0.3 0.1
Low risk (1–2 VD) 65.5 52.4
High Risk (2–3 VD) 28.6 37.1
Left Main disease 5.4 10.3
SD: Standard deviation, BMI: body mass index, CVD: Cerebrovascular disease, PVD:
Peripheral vascular disease, MI: myocardial infarction, PCI: Percutaneous Coronary
Intervention, CABG: Coronary Artery Bypass Grafting, ACS: Acute coronary
syndrome, VD: vessel disease. *Other include silence ischemia, evaluation of
serious arrhythmia, preoperative assessment, research protocol angiography.
Table 3 Baseline characteristics by smoking status at one
year after angiography (Cohort A)





No. (%) 1064 (41.2) 1519 (58.8)
BMI, Mean (SD) 28.6 (5.6) 28.8 (5.2) 0.4
Age, Mean (SD) 58.4 (9.6) 58.9 (9.9) 0.3
Female (%) 27.3 19.0 <0.001
Diabetes Mellitus (%) 19.0 20.1 0.5
Hyperlipidemia (%) 79.7 78.9 0.6
Pulmonary disease (%) 15.3 13.1 0.1
Heart Failure (%) 8.4 9.6 0.3
Hypertension (%) 63.1 62.3 0.7
CVD (%) 4.4 3.9 0.6
PVD (%) 8.9 6.1 0.007
ST-Elevated MI (%) 34.7 40.6 0.002
Non ST-Elevated MI (%) 27.3 30.7 0.07
Prior MI (%) 26.2 23.9 0.2
Prior PCI (%) 3.8 3.0 0.3
Prior CABG (%) 1.3 1.4 0.9
Prior lytic (%) 8.6 12.0 0.006
ACS (%) 70.2 76.4 0.001
Indication for angiography (%) <0.001
Acute/recent MI 55.0 63.5
Unstable angina 16.1 14.5
Stable angina 24.9 17.8
Other* 4.0 4.2
Priority to angiography (%) 0.01
Emergency 13.8 17.7
Urgent in hospital 58.2 59.5
Urgent out of hospital 10.1 8.6
Planned 16.5 13.0
Unknown 1.4 1.2





Not done 14.9 16.0
Coronary Anatomy (%) <0.001
Normal 0.0 0.1
<50% disease 0.0 0.2
Low risk (1–2 VD) 69.9 55.2
High Risk (2–3 VD) 25.1 35.0
Left Main disease 4.9 9.5
SD: Standard deviation, BMI: body mass index, CVD: Cerebrovascular disease, PVD:
Peripheral vascular disease, MI: myocardial infarction, PCI: Percutaneous Coronary
Intervention, CABG: Coronary Artery Bypass Grafting, ACS: Acute coronary
syndrome, VD: vessel disease. *Other include silence ischemia, evaluation of
serious arrhythmia, preoperative assessment, research protocol angiography.
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Table 4 Baseline characteristics stratified by treatment
(Cohort B)
Clinical characteristics Medical Revascularization p-value
No. 2123 2123
BMI, Mean (SD) 28.8 (5.6) 28.8 (5.2) 1
Age, Mean (SD) 66.5 (10.8) 66 (10.3) 0.2
Female (%) 24.6 25.4 0.6
Current smoker (%) 18.6 18.5 1
Renal disease (%) 3.9 3.9 1
Liver/ GI disease (%) 8.2 8.9 0.4
Diabetes Mellitus (%) 26.6 25.6 0.4
Hyperlipidemia (%) 78.8 78.9 1
Malignancies (%) 5.1 5.3 0.7
Pulmonary disease (%) 16.9 17.2 0.8
Heart Failure (%) 13.8 12.0 0.07
Hypertension (%) 72.4 72.5 1
CVD (%) 7.6 8.0 0.7
PVD (%) 8.6 8.7 0.9
ST-Elevated MI (%) 11.4 10.7 0.5
Non ST-Elevated MI (%) 18.8 18.6 0.8
Prior MI (%) 28.0 27.5 0.7
Prior PCI (%) 5.9 6.2 0.6
Prior CABG (%) 7.2 5.9 0.1
Prior lytic (%) 2.7 2.7 1
ACS (%) 42.1 41.9 0.9
Indication for angiography (%) 0.9
Acute/recent MI 26.1 25.5
Unstable angina 17.1 17.6
Stable angina 49.3 49.0
Other* 7.5 7.9





Not done 7.0 6.2
Coronary Anatomy (%) 0.7
Normal 0.2 0
<50% disease 0.3 0.3
Low risk (1–2 VD) 66.1 67.2
High Risk (2–3 VD) 28.3 27.5
Left Main disease 5.1 4.9
SD: Standard deviation, BMI: body mass index, CVD: Cerebrovascular disease,
PVD: Peripheral vascular disease, MI: myocardial infarction, PCI: Percutaneous
Coronary Intervention, CABG: Coronary Artery Bypass Grafting, ACS: Acute
coronary syndrome, VD: vessel disease. *Other include silence ischemia,
evaluation of serious arrhythmia, preoperative assessment, research
protocol angiography.
Table 5 Treatments received after first treatment during
follow-up period (Cohort B)
First treatment after catheterization
Medical CABG PCI
N % N % N %
Secondary
treatment
None 1818 85.6 487 87.1 1359 86.9
PCI 95 4.5 39 7.0 59 3.8
CABG 124 5.8 21 3.8 73 4.7
Lytic 56 2.6 3 0.5 47 3.0
PCI & Lytic 1 0.0 0 0.0 3 0.2
CABG & Lytic 0 0.0 0 0.0 1 0.1
PCI & CABG 28 1.3 7 1.3 21 1.3
PCI & CABG & Lytic 1 0 2 0.4 1 0.1
Total 2123 100.0 559 100.0 1564 100.0
PCI: Percutaneous Coronary Intervention, CABG: Coronary Artery Bypass Grafting.
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with a survival benefit relative to continuing to smoke is
overwhelming. These data, first elegantly described in a
prospective cohort study by Richard Doll in the British
Doctors Study [20], have been recently re-enforced by the
Nurses’ Health Study conducted in over 100,000 women
between 1982 and 2004 [21]. In a systematic review of
twenty observational non-randomized studies, Critchley
et al. [22] found that quitting smoking was associated
with substantial risk reduction (36%) of all-cause mor-
tality among patients with CAD. The risk reduction
for other secondary prevention measures was 29% for sta-
tins [23], 15% for Aspirin [24], 23% for β-blockers
[25], and 23% for angiotensin converting enzyme in-
hibitors [26]. An earlier systematic review found compar-
able risk reduction [27].
Among patients with CAD, quitting smoking reduces
the risk of recurrent events, improves patients’ quality of
life and is cost-effective [28,29]. Compared with other
secondary preventive measures, smoking cessation is
both an effective and cost-effective intervention [18,22].
Our data provide an impetus to health systems, policy
makers and patients to ensure this remains a focus of
care regardless of the CAD management strategy. The
Canadian Cardiovascular Society has emphasised the pri-
ority of identifying and documenting smoking status and
providing smoking cessation support for all smokers ad-
mitted to hospital with CAD [10]. The outcome of imple-
menting such programs highly depends on the program
structure and duration. Short inpatient education pro-
grams have not increased smoking cessation rates at one
year and at five years [30]. More intensive behavioral in-
terventions with at least one month of supportive contacts
after hospital discharge increased cessation rates [31,32],
as does add pharmacological management [30,33].
Table 6 Treatment association with self-reported smoking status at 1 year post angiography
Smoking status at Treatment χ2 (p-value)
MT no. (%) CABG no. (%) PCI no. (%) MT vs. CABG MT vs. PCI CABG vs. PCI
Cohort A smokers quit at one year 217 (47.6) 353 (74.3) 949 (57.4) 69.9 (<0.001) 14.0 (<0.001) 44.2 (<0.001)
Cohort B smokers quit at one year 185 (47.0) 65 (68.4) 111 (37.4) 14.11 (<0.001) 6.35 (0.007) 28.05 (<0.001)
PCI: Percutaneous Coronary Intervention, CABG: Coronary Artery Bypass Grafting.
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groups when data were analysed into two successive
45-month periods. These findings could be a reflection of
an improvement in CAD management strategies. Despite
this, we found long-term survival rates were consistently
lower among patients with CAD who smoked compared
to non-smokers or smokers who quit smoking. The ob-
served reduction in mortality is similar to the results re-
ported in the Coronary Artery Surgery Study after 10 years
of follow-up [34], where patients who continued to smoke
had significantly lower survival rates compared with quit-
ters in CABG group (84% vs. 68%, p = 0.018) and not a sig-
nificant difference for patients in the medical treatment
arm (75% vs. 71%).
Observations that smokers had decreased mortality
rates following acute myocardial infarction, in the era
when fibrinolysis was the leading reperfusion strategy,
have introduced the term “smokers’ paradox” to the med-
ical literature. However, our findings, as well other recent
studies do not support this observation [35]. Likewise, a
recent systematic review reported that all contemporary
studies that follow-up with patients for longer than oneTable 7 Survival analysis
Cohort A (Unmatched)




Smokers 1064 85 979 92.0%
Smokers who quit
at one year
1519 65 1454 95.7%
Non-smokers 8606 610 7996 92.9%
Cohort B (matched)





Smokers 209 25 184 88.0%
Smokers who quit
at one year
185 13 172 93.0%
Non-smokers 1697 184 1513 89.2%
RV
Smokers*§ 216 24 192 88.9%
Smokers who quit
at one year
176 9 167 94.9%
Non-smokers 1699 123 1576 92.8%
*Log rank significance compared to smokers who quit at one year < 0.05.
§Log rank significance compared to non-smokers < 0.05.
MT: Medical Treatment; RV: Revascularization.year do not have evidence for such paradox attributing the
existence of this phenomenon to the difference in the
baseline risk and comorbidities, to the difference in the
pathogenesis of acute coronary events between smokers
and non-smokers, or to methodological errors in studies
[36]. Our data lend further evidence that quitting smok-
ing, particularly if revascularization has been performed, is
beneficial.
We have shown in our study, albeit in a relatively
small sample size, a trend of greater long term survival
rate for smokers who self-reported quitting at one year
compared with non-smokers. The mechanisms under-
lying this effect were not the focus of this study. How-
ever, the deleterious consequences of smoking on stress
hormone release, blood pressure, thrombotic tendency
and vascular biology have been well described and
aptly summarized in a recent review by Messner and
Bernard [37].
Strengths and limitations
This study used data from an observational registry and
has limitations that generally apply to observational ana-
lyses. The APPROACH registry captures all patients for
the catchment area in Alberta (population 3.5 million)
and has complete data on all patients undergoing angi-
ography in the province and their subsequent treatment
and outcome. Hence, it is highly generalizable and re-
flects clinical care but may not be able to capture all
variables that influence survival or would eliminate or
enhance any of our statistically significant results. Vari-
ables usually absent from larger observational datasets
including number of diseased coronary arteries, EF and
coronary anatomy are available enhancing the ability to
better describe the population being studied. Propensity-
based matching attempts to eliminate other bias asso-
ciated with conventional multivariable modeling and
treatment selection. This study used self-reported smok-
ing cessation rates to assess smoking status and survey
methodology. Although biochemical validation of smoking
status is considered a more robust method in assessing
cessation, self-reported cessation rates are still a reliable
method in assessing smoking status in patients admitted
to hospital [38]. Unfortunately, we do not know the dur-
ation of smoking history or life time exposure to tobacco
of our population; these data were not included in the
Approach database.
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Our data indicate that smokers who have undergone
CABG were more likely to report smoking cessation at
one year following the angiography than those who are
treated with PCI or MT. Quitting smoking is associ-
ated with improved long-term survival, particularly among
revascularized patients. Smoking remains an undertreated
risk factor among patients with angiographically proven
CAD. Quitting smoking should be a key objective of man-
agement in patients with CAD.
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